Funded by grants from the Worldwide Cancer Research in the United Kingdom, and Mater Foundation, the new vaccine could be potentially used to treat a variety of blood cancers and malignancies.
Lead Researcher Associate Professor Kristen Radford says the study is a major breakthrough for cancer vaccinations.
“We are hoping this vaccine could be used to treat blood cancers, (myeloid leukaemia, non-Hodgkin’s lymphoma, multiple myeloma, and paediatric leukaemias) plus solid malignancies including breast, lung, renal, ovarian, and pancreatic cancers, and glioblastoma,” she said.
“Our new vaccine is comprised of human antibodies fused with tumour-specific protein, and we are investigating its capacity to target human cells while activating the memory of the tumour cells.”
Associate Professor Radford explains that the vaccine offers several key advantages over existing cancer vaccines, which have already shown promise in early clinical trials.
“First, it can be produced as an ‘off the shelf’ clinical grade formulation, which circumvents the ﬁnancial and logistical issues associated with patient-speciﬁc vaccines,” she said.
“Secondly, this prototype vaccine targets the key tumour cells required for the initiation of tumour-speciﬁc immune responses, thereby maximising potential effectiveness of treatment, while minimising potential side effects.
“We are very happy to see our research published in a prestigious journal, and we hope our continued work towards finding a safe and effective cancer vaccine will benefit cancer patients in the future.”
The study was published in the highly ranked journal Clinical and Translational Immunology.
A/Prof Radford is currently seeking funding to trial the vaccine in patients. Donations for a trial can be made via the Mater Foundation.
This article was first published by Mater Research.